15-20 National Hospital

Company

15-20 National Hospital develops one asset, in phase 1 (GS030 in retinitis pigmentosa). Mostly gene therapy.

1
Asset
Furthest stage
Phase 1
0
Trials
1
Signal

Pipeline

1
  • GS030

    Optogenetic gene therapy encoding a channelrhodopsin to restore light sensitivity in retinal ganglion cells

    Phase 1, Gene therapy, retinitis pigmentosa, Partner

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Signals1
  • Similar companies5

Intelligence